Trial Profile

An Ex-U.S. Proof-of-Concept Clinical Trial of ALG-1007 for the Treatment of Dry Eye Disease (DED)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALG 1007 (Primary)
Indications Dry eyes
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

08 Oct 2019 According to an Allegro Ophthalmics media release, data from the study will be presented during AAO 2019, the American Academy of Ophthalmology's 123rd annual meeting.
03 Sep 2019 According to an Allegro Ophthalmics media release, data from the study will be presented during the 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) 2019.
14 May 2019 Results presented in the Allegro Ophthalmics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com